|
|
Post by theanalystfromhell on Jul 25, 2014 1:34:42 GMT -5
Contract Sales Organization...
Many big pharma companies are laying off their sales force and opting to use CSOs. They work for a percentage of sales on a tiered sales model. The more they sell, the higher the percentage of the higher tier sales they get. This could end up being the route MNKD goes, they don't need much upfront cash. They need revenues. The CSO world is locked in a cut-throat race to the bottom, and the companies can be played against each other for leverage. Announcement of one of more CSO partners will do more for the long term potential of this stock than any bloated big pharma partner you can imagine.
Industry insider...
|
|
|
|
Post by rak5555 on Jul 25, 2014 9:03:54 GMT -5
I would agree except that mnkd needs more than just sales support. They also need money and FDA expertise. There will be a plethora of post marketing clinical trials to expand and improve the label. Even though afrezza has achieved approval, there have been too many slips along the way.
|
|
|
|
Post by mannmade on Jul 25, 2014 9:22:28 GMT -5
Also they need a global presence and filing for EU, and marketing expertise. Plus they have other drugs they need to focus on developing...
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 25, 2014 12:44:45 GMT -5
I think that it is a dark horse contender at this point. My fave pick for the last several months has been AmerisourceBergen. At first, I was tongue-in-cheek, just saying it to explore the possibility, but I think AmerisourceBergen is at least as probable as any individual drug manufacturer.
But rak5555 is right - it would require a _lot_ of cash. Who knows - maybe Al would open up his pockets and take on an additional 10% ownership in order to inject the cash necessary for launch (would keep him under 50%), or there's the possibility of a 100M share offering, since MNKD is authorized up to 550M shares.
The bright side would be that MNKD would keep all profits, and if you believe that Afrezza will grab a large chunk of market share, then that could be best in the long term.
|
|
|
|
Post by thsloppy on Jul 25, 2014 13:00:10 GMT -5
dude...scary.
Anyway..I'm not a fan of this for a company at this stage for 2 reasons. First, I've used contract forces before and they are fine for certain applications where any walking commercial will work. For a product like this, there has to be a different level of buy in at the rep level and a different skill set to really communicate at the physician level. Secondly, there needs to be a different level of expertise from the partner with regards to trials, post market follow up etc. This needs to be a long term committed partnership with real capabilities. I'd prefer to go 2nd tier pharm.'s or regional partnerships before going contract.
|
|
|
|
Post by seanismorris on Jul 26, 2014 23:33:54 GMT -5
I'm going to have to agree that using a CSO isn't the answer.
Mannkind needs the partnership, they need a specialized marketing team that has an established relationship with Doctors, they need the cash from the partnership to expand manufacturing and to pay for dozens of new hires (this past week they were looking for numerous QC people -just because the initial production lines are in place doesn't mean they have the personnel to run them).
Mannkind is also looking at getting approval in Europe and around the world. This will be the partners responsibility, they don't have the experience in house. The list goes on and on...
What it comes down too, is Mannkind need a successful launch which means no CSO at this point. They could use one at some point, but doing so at this stage would be a disaster.
|
|
